Sun Zhaoli, Williams George Melville
Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Chimerism. 2011 Oct-Dec;2(4):120-2. doi: 10.4161/chim.2.4.19177.
Liver transplant has become life-saving therapy for thousands of patients with end stage liver disease in the United States, but chronic rejection and the toxicities of immunosuppression remain significant obstacles to the further expansion of this modality and "transplant tolerance" remains a central goal in the field. So we and others are looking for alternative post-transplant strategies. We set out to 'engineer' repopulation after transplantation in a strain combination [dark agouti (DA) to Lewis green fluorescent protein+ (LEW GFP+)] which rejects liver grafts strongly, a model that more closely resembles the situation in humans. Our central finding is purposeful manipulation of the immune response with low dose immunosuppression and liberation of stem cells for a very short period after transplantation results in long-term transplant acceptance by two mechanisms: transforming the liver (donor) to self (host) phenotype, and auto-suppression of the specific allograft response.
在美国,肝移植已成为数千名终末期肝病患者的救命疗法,但慢性排斥反应和免疫抑制的毒性仍是这种治疗方式进一步推广的重大障碍,“移植耐受”仍是该领域的核心目标。因此,我们和其他研究人员正在寻找移植后的替代策略。我们着手在一种强烈排斥肝移植的品系组合(从黑褐毛豚鼠(DA)到绿色荧光蛋白阳性的刘易斯大鼠(LEW GFP+))中“设计”移植后的肝再生,该模型更接近人类的情况。我们的核心发现是,在移植后极短时间内,通过低剂量免疫抑制有目的地操纵免疫反应并释放干细胞,可通过两种机制实现长期移植耐受:将肝脏(供体)转变为自身(宿主)表型,以及对特定同种异体移植反应的自身抑制。